An example of drugs targeting at PDE4 currently in clinical use is roflumilast, a selective inhibitor mainly prescribed to patients with severe COPD [19], resulting in decreased airway inflammation and frequency of exacerbation [20]. Here, PDE4A is linked to chronic obstructive pulmonary disease.